Your browser doesn't support javascript.
loading
Data on the stability of darunavir/cobicistat suspension after tablet manipulation.
Zanon, D; Manca, A; De Nicolò, A; D'Avolio, A; Musazzi, U M; Cilurzo, F; Maximova, N; Tomasello, C; Minghetti, P.
Afiliación
  • Zanon D; Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  • Manca A; Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
  • De Nicolò A; Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
  • D'Avolio A; Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
  • Musazzi UM; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.
  • Cilurzo F; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.
  • Maximova N; Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  • Tomasello C; S.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin, Italy.
  • Minghetti P; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy.
Data Brief ; 30: 105552, 2020 Jun.
Article en En | MEDLINE | ID: mdl-32292805
The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients' need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Data Brief Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Data Brief Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Países Bajos